Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism.
Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs.
Value-positioned RTD iced tea from PepsiCo-Unilever joint venture; bold flavors at accessible prices in convenience stores competing with AriZona in mainstream tea.
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positioned itself as a bold, value-priced iced tea targeting younger consumers who wanted flavorful, refreshing beverages at affordable prices — often sold in large cans and bottles that delivered more volume at lower per-ounce costs than premium tea brands. The brand's irreverent advertising featuring clay-animated celebrities became culturally memorable.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.